ArticleTranslational cancer research2026
Prognostic value of DNA methylation in head and neck cancer: a systematic review and meta-analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical relevance of DNA methylation in head and neck cancer (HNC) is increasingly recognized, yet controversies persist regarding its prognostic significance. We conducted a systematic review and meta-analysis adhering to the PRISMA 2020 guidelines to synthesize evidence on this association. Methods: A comprehensive literature search was performed across five databases (PubMed, Web of Science Core Collection, Cochrane Library, Embase, and Scopus) from inception to October 31, 2025. Eligible studies included original clinical investigations (prospective/retrospective cohort, case-control) reporting prognostic outcomes [overall survival (OS), disease-free survival (DFS)] stratified by DNA methylation status in histologically confirmed HNC patients. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results: Nineteen studies involving 3,251 patients were included. High DNA methylation was significantly associated with poor prognosis in HNC: OS (HR =1.50, 95% CI: 1.19-1.90, P=0.001) and DFS (HR =2.44, 95% CI: 1.74-3.47, P<0.001). Significant heterogeneity was observed for OS (I Conclusions: DNA methylation plays a pivotal role in HNC carcinogenesis and progression, emerging as a robust and promising prognostic biomarker. However, its predictive value for treatment response remains unproven, requiring further investigation in treatment-stratified cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.